Global PD-1 and PD-L1 Inhibitors Market Insights and Forecast to 2027

1 Study Coverage

• 1.1 PD-1 and PD-L1 Inhibitors Product Introduction
• 1.2 Market by Type
  • 1.2.1 Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Type
  • 1.4.2 PD-1 Inhibitors
  • 1.4.3 PD-L1 Inhibitors
• 1.3 Market by Application
  • 1.3.1 Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Application
  • 1.3.2 Solid Tumors
  • 1.3.3 Blood-related Tumors
• 1.4 Study Objectives
• 1.5 Years Considered

2 Executive Summary

• 2.1 Global PD-1 and PD-L1 Inhibitors Sales Estimates and Forecasts 2016-2027
• 2.2 Global PD-1 and PD-L1 Inhibitors Revenue Estimates and Forecasts 2016-2027
• 2.3 Global PD-1 and PD-L1 Inhibitors Revenue by Region: 2016 VS 2021 VS 2027
• 2.4 Global Top PD-1 and PD-L1 Inhibitors Regions by Sales
  • 2.4.1 Global Top PD-1 and PD-L1 Inhibitors Regions by Sales (2016-2021)
  • 2.4.2 Global Top PD-1 and PD-L1 Inhibitors Regions by Sales (2022-2027)
• 2.5 Global Top PD-1 and PD-L1 Inhibitors Regions by Revenue
  • 2.5.1 Global Top PD-1 and PD-L1 Inhibitors Regions by Revenue (2016-2021)
  • 2.5.2 Global Top PD-1 and PD-L1 Inhibitors Regions by Revenue (2022-2027)
• 2.6 North America
• 2.7 Europe
• 2.8 Asia-Pacific
• 2.9 Latin America
• 2.10 Middle East & Africa

3 Competition by Manufacturers

• 3.1 Global PD-1 and PD-L1 Inhibitors Sales by Manufacturers
  • 3.1.1 Global Top PD-1 and PD-L1 Inhibitors Manufacturers by Sales (2016-2021)
  • 3.1.2 Global Top PD-1 and PD-L1 Inhibitors Manufacturers Market Share by Sales (2016-2021)
  • 3.1.3 Global Top 10 and Top 5 Companies by PD-1 and PD-L1 Inhibitors Sales in 2020
• 3.2 Global PD-1 and PD-L1 Inhibitors Revenue by Manufacturers
  • 3.2.1 Global Top PD-1 and PD-L1 Inhibitors Manufacturers by Revenue (2016-2021)
  • 3.2.2 Global Top PD-1 and PD-L1 Inhibitors Manufacturers Market Share by Revenue (2016-2021)
  • 3.2.3 Global Top 10 and Top 5 Companies by PD-1 and PD-L1 Inhibitors Revenue in 2020
• 3.3 Global PD-1 and PD-L1 Inhibitors Sales Price by Manufacturers
• 3.4 Analysis of Competitive Landscape
  • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global PD-1 and PD-L1 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.4.3 Global PD-1 and PD-L1 Inhibitors Manufacturers Geographical Distribution
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Global PD-1 and PD-L1 Inhibitors Sales by Type
  • 4.1.1 Global PD-1 and PD-L1 Inhibitors Historical Sales by Type (2016-2021)
  • 4.1.2 Global PD-1 and PD-L1 Inhibitors Forecasted Sales by Type (2022-2027)
  • 4.1.3 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2016-2027)
• 4.2 Global PD-1 and PD-L1 Inhibitors Revenue by Type
  • 4.2.1 Global PD-1 and PD-L1 Inhibitors Historical Revenue by Type (2016-2021)
  • 4.2.2 Global PD-1 and PD-L1 Inhibitors Forecasted Revenue by Type (2022-2027)
  • 4.2.3 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2016-2027)
• 4.3 Global PD-1 and PD-L1 Inhibitors Price by Type
  • 4.3.1 Global PD-1 and PD-L1 Inhibitors Price by Type (2016-2021)
  • 4.3.2 Global PD-1 and PD-L1 Inhibitors Price Forecast by Type (2022-2027)

5 Market Size by Application

• 5.1 Global PD-1 and PD-L1 Inhibitors Sales by Application
  • 5.1.1 Global PD-1 and PD-L1 Inhibitors Historical Sales by Application (2016-2021)
  • 5.1.2 Global PD-1 and PD-L1 Inhibitors Forecasted Sales by Application (2022-2027)
  • 5.1.3 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2016-2027)
• 5.2 Global PD-1 and PD-L1 Inhibitors Revenue by Application
  • 5.2.1 Global PD-1 and PD-L1 Inhibitors Historical Revenue by Application (2016-2021)
  • 5.2.2 Global PD-1 and PD-L1 Inhibitors Forecasted Revenue by Application (2022-2027)
  • 5.2.3 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2016-2027)
• 5.3 Global PD-1 and PD-L1 Inhibitors Price by Application
  • 5.3.1 Global PD-1 and PD-L1 Inhibitors Price by Application (2016-2021)
  • 5.3.2 Global PD-1 and PD-L1 Inhibitors Price Forecast by Application (2022-2027)

6 North America

• 6.1 North America PD-1 and PD-L1 Inhibitors Market Size by Type
  • 6.1.1 North America PD-1 and PD-L1 Inhibitors Sales by Type (2016-2027)
  • 6.1.2 North America PD-1 and PD-L1 Inhibitors Revenue by Type (2016-2027)
• 6.2 North America PD-1 and PD-L1 Inhibitors Market Size by Application
  • 6.2.1 North America PD-1 and PD-L1 Inhibitors Sales by Application (2016-2027)
  • 6.2.2 North America PD-1 and PD-L1 Inhibitors Revenue by Application (2016-2027)
• 6.3 North America PD-1 and PD-L1 Inhibitors Market Size by Country
  • 6.3.1 North America PD-1 and PD-L1 Inhibitors Sales by Country (2016-2027)
  • 6.3.2 North America PD-1 and PD-L1 Inhibitors Revenue by Country (2016-2027)
  • 6.3.3 U.S.
  • 6.3.4 Canada

7 Europe

• 7.1 Europe PD-1 and PD-L1 Inhibitors Market Size by Type
  • 7.1.1 Europe PD-1 and PD-L1 Inhibitors Sales by Type (2017-2027)
  • 7.1.2 Europe PD-1 and PD-L1 Inhibitors Revenue by Type (2017-2027)
• 7.2 Europe PD-1 and PD-L1 Inhibitors Market Size by Application
  • 7.2.1 Europe PD-1 and PD-L1 Inhibitors Sales by Application (2017-2027)
  • 7.2.2 Europe PD-1 and PD-L1 Inhibitors Revenue by Application (2017-2027)
• 7.3 Europe PD-1 and PD-L1 Inhibitors Market Size by Country
  • 7.3.1 Europe PD-1 and PD-L1 Inhibitors Sales by Country (2017-2027)
  • 7.3.2 Europe PD-1 and PD-L1 Inhibitors Revenue by Country (2017-2027)
  • 7.3.3 Germany
  • 7.3.4 France
  • 7.3.5 U.K.
  • 7.3.6 Italy
  • 7.3.7 Russia

8 Asia Pacific

• 8.1 Asia Pacific PD-1 and PD-L1 Inhibitors Market Size by Type
  • 8.1.1 Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Type (2018-2027)
  • 8.1.2 Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Type (2018-2027)
• 8.2 Asia Pacific PD-1 and PD-L1 Inhibitors Market Size by Application
  • 8.2.1 Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Application (2018-2027)
  • 8.2.2 Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Application (2018-2027)
• 8.3 Asia Pacific PD-1 and PD-L1 Inhibitors Market Size by Region
  • 8.3.1 Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Region (2018-2027)
  • 8.3.2 Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Region (2018-2027)
  • 8.3.3 China
  • 8.3.4 Japan
  • 8.3.5 South Korea
  • 8.3.6 India
  • 8.3.7 Australia
  • 8.3.8 Taiwan
  • 8.3.9 Indonesia
  • 8.3.10 Thailand
  • 8.3.11 Malaysia
  • 8.3.12 Philippines

9 Latin America

• 9.1 Latin America PD-1 and PD-L1 Inhibitors Market Size by Type
  • 9.1.1 Latin America PD-1 and PD-L1 Inhibitors Sales by Type (2019-2027)
  • 9.1.2 Latin America PD-1 and PD-L1 Inhibitors Revenue by Type (2019-2027)
• 9.2 Latin America PD-1 and PD-L1 Inhibitors Market Size by Application
  • 9.2.1 Latin America PD-1 and PD-L1 Inhibitors Sales by Application (2019-2027)
  • 9.2.2 Latin America PD-1 and PD-L1 Inhibitors Revenue by Application (2019-2027)
• 9.3 Latin America PD-1 and PD-L1 Inhibitors Market Size by Country
  • 9.3.1 Latin America PD-1 and PD-L1 Inhibitors Sales by Country (2019-2027)
  • 9.3.2 Latin America PD-1 and PD-L1 Inhibitors Revenue by Country (2019-2027)
  • 9.3.3 Mexico
  • 9.3.4 Brazil
  • 9.3.5 Argentina

6 Middle East and Africa

• 6.1 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Size by Type
  • 6.1.1 Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Type (2016-2027)
  • 6.1.2 Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Type (2016-2027)
• 6.2 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Size by Application
  • 6.2.1 Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Application (2016-2027)
  • 6.2.2 Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Application (2016-2027)
• 6.3 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Size by Country
  • 6.3.1 Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Country (2016-2027)
  • 6.3.2 Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Country (2016-2027)
  • 6.3.3 Turkey
  • 6.3.4 Saudi Arabia
  • 6.3.5 UAE

11 Company Profiles

• 11.1 Merck
  • 11.1.1 Merck Corporation Information
  • 11.1.2 Merck Overview
  • 11.1.3 Merck PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.1.4 Merck PD-1 and PD-L1 Inhibitors Product Description
  • 11.1.5 Merck Related Developments
• 11.2 Bristol-Myers Squibb
  • 11.2.1 Bristol-Myers Squibb Corporation Information
  • 11.2.2 Bristol-Myers Squibb Overview
  • 11.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Description
  • 11.2.5 Bristol-Myers Squibb Related Developments
• 11.3 Roche
  • 11.3.1 Roche Corporation Information
  • 11.3.2 Roche Overview
  • 11.3.3 Roche PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.3.4 Roche PD-1 and PD-L1 Inhibitors Product Description
  • 11.3.5 Roche Related Developments
• 11.4 AstraZeneca
  • 11.4.1 AstraZeneca Corporation Information
  • 11.4.2 AstraZeneca Overview
  • 11.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.4.4 AstraZeneca PD-1 and PD-L1 Inhibitors Product Description
  • 11.4.5 AstraZeneca Related Developments
• 11.5 Ono Pharmaceutical
  • 11.5.1 Ono Pharmaceutical Corporation Information
  • 11.5.2 Ono Pharmaceutical Overview
  • 11.5.3 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.5.4 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Description
  • 11.5.5 Ono Pharmaceutical Related Developments
• 11.6 Regeneron
  • 11.6.1 Regeneron Corporation Information
  • 11.6.2 Regeneron Overview
  • 11.6.3 Regeneron PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.6.4 Regeneron PD-1 and PD-L1 Inhibitors Product Description
  • 11.6.5 Regeneron Related Developments
• 11.7 Innovent
  • 11.7.1 Innovent Corporation Information
  • 11.7.2 Innovent Overview
  • 11.7.3 Innovent PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.7.4 Innovent PD-1 and PD-L1 Inhibitors Product Description
  • 11.7.5 Innovent Related Developments
• 11.8 Hengrui Medicine
  • 11.8.1 Hengrui Medicine Corporation Information
  • 11.8.2 Hengrui Medicine Overview
  • 11.8.3 Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.8.4 Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Description
  • 11.8.5 Hengrui Medicine Related Developments
• 11.9 Junshi Biosciences
  • 11.9.1 Junshi Biosciences Corporation Information
  • 11.9.2 Junshi Biosciences Overview
  • 11.9.3 Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.9.4 Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Description
  • 11.9.5 Junshi Biosciences Related Developments
• 11.10 Merck KGaA
  • 11.10.1 Merck KGaA Corporation Information
  • 11.10.2 Merck KGaA Overview
  • 11.10.3 Merck KGaA PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.10.4 Merck KGaA PD-1 and PD-L1 Inhibitors Product Description
  • 11.10.5 Merck KGaA Related Developments
• 11.1 Merck
  • 11.1.1 Merck Corporation Information
  • 11.1.2 Merck Overview
  • 11.1.3 Merck PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.1.4 Merck PD-1 and PD-L1 Inhibitors Product Description
  • 11.1.5 Merck Related Developments

12 Value Chain and Sales Channels Analysis

• 12.1 PD-1 and PD-L1 Inhibitors Value Chain Analysis
• 12.2 PD-1 and PD-L1 Inhibitors Key Raw Materials
  • 12.2.1 Key Raw Materials
  • 12.2.2 Raw Materials Key Suppliers
• 12.3 PD-1 and PD-L1 Inhibitors Production Mode & Process
• 12.4 PD-1 and PD-L1 Inhibitors Sales and Marketing
  • 12.4.1 PD-1 and PD-L1 Inhibitors Sales Channels
  • 12.4.2 PD-1 and PD-L1 Inhibitors Distributors
• 12.5 PD-1 and PD-L1 Inhibitors Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

• 13.1 PD-1 and PD-L1 Inhibitors Industry Trends
• 13.2 PD-1 and PD-L1 Inhibitors Market Drivers
• 13.3 PD-1 and PD-L1 Inhibitors Market Challenges
• 13.4 PD-1 and PD-L1 Inhibitors Market Restraints

14 Key Findings in The Global PD-1 and PD-L1 Inhibitors Study

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Author Details